Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation - Wikidata - awgldk - TriplyDB

Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation

Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation

http://www.wikidata.org/entity/Q30431207

about

Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation Prophylactic managements of hepatitis B viral infection in liver transplantation Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome Management of patients with hepatitis B in special populations Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Progress in hepatitis B: a 30-year journey through three continents.Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience.Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation.Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers.Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.Prophylaxis of hepatitis B infection in solid organ transplant recipients.Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B.The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation.Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation.Hepatitis B immune globulin in liver transplantation prophylaxis: an update.High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity.Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving alternative.Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.

P2860

Q26751777-885E63AC-6B0D-4744-A783-ED0E851E3F65 Q26772340-EA3DA511-AC91-40E5-8401-C049F3B95812 Q26784241-CC2EA124-602C-459C-9E8F-CE897981000E Q26859121-AFFA1BA2-016C-43DE-B3BF-69C45A05895F Q27016136-A302D8CD-4B23-4895-B29F-0C16CF7C402F Q30391932-82EA6EB4-1588-4329-B3C2-1CBA56351962 Q33831416-125231E7-2186-45A3-8CB5-057D3F211512 Q34029115-52100777-009B-4731-9FC7-604625FA1306 Q34171703-44E72DB4-4D28-4C8A-8C90-7649D3600AF4 Q34959703-4B285FC0-63BC-46FE-B034-06B46DB2168B Q36254143-5AD0B6F4-E928-465A-A704-94DD22294CCB Q36745425-17AD4DBB-BBB3-4621-A5A1-011CDB688AE1 Q36886518-2EAA8594-C1EC-4C74-A3FD-FAD2D11CBC4E Q37217853-EEA6C4B7-621A-4C03-B208-E902572386A3 Q37870833-3EB53708-3CCA-4F20-BBF2-543BCF0AC6C6 Q37886893-7D1E1E4A-734F-4943-BECA-CCDC6C59C43D Q37905782-2EC4F7A0-73B0-4970-BCB6-1E31BDD78479 Q37982346-104863D2-D312-4649-ACA2-D9A42B112D7F Q38006958-001B5E21-E0AC-4432-8892-D8107FBDBD61 Q38058545-FE7B0E71-F4AE-4EFB-B13E-56890AA439DF Q38137238-DB41ACF4-3632-4D9C-9C52-A44646438799 Q38514411-044006E0-DC41-4FB9-B402-F98FBCBBCCE0 Q38685587-1179A3F2-92EB-4941-8AFC-6C82BB76559E Q39372160-F587CD83-CB30-48DA-968E-8ABFA4F6E9AB Q40356307-76119F3B-7EF5-4405-8609-56EB63485B4B Q40641923-2B848E2A-C7E4-4796-83D8-D626061C12C6 Q40654117-5DCA3E4F-D73A-4810-82B8-4552DD2C157A Q41755402-E8653F26-4C80-436A-A0F5-3A595CCF880F Q42263202-E2C720E5-CD0C-4D8F-BD45-C1951A8C3576 Q44313001-256BC7A9-C391-4330-89B1-ACE52381CFAF Q44966178-CBF0700E-DC8C-450F-8DFA-B3F801F2CDAE Q44973263-F69E88CE-3307-408D-B231-F4AC7901263E Q45352477-10EC1698-03C8-45C9-A6B1-9F0344660787

P2860

Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation

http://www.wikidata.org/entity/Q30431207

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Impact of virologic breakthrou ...... ce after liver transplantation

@ast

Impact of virologic breakthrou ...... ce after liver transplantation

@en

type

label

Impact of virologic breakthrou ...... ce after liver transplantation

@ast

Impact of virologic breakthrou ...... ce after liver transplantation

@en

prefLabel

Impact of virologic breakthrou ...... ce after liver transplantation

@ast

Impact of virologic breakthrou ...... ce after liver transplantation

@en

P1433

Q30431207-2C85A14D-DA41-4911-82ED-E1DFDAE8D0A5

P1476

Q30431207-0164D097-1C4A-41F4-86E2-0190F55BB9EE

P2093

Q30431207-2AB03D38-982D-48FC-9E02-0BE031DC851C

Q30431207-41EEB99C-A7B5-4909-9E8D-D6E78CBFE9AD

Q30431207-487D223D-41FE-4EF7-BD22-987026D9D95D

Q30431207-5B539349-7BA5-47A1-928D-B65F10638B2D

Q30431207-7D5832D3-4BF4-4E7D-8E25-13D5C1360FC6

Q30431207-8041447C-19C4-43F8-87B5-997B5315D62B

Q30431207-95785689-B6A4-4E30-A1E4-2BFFE89EFC69

Q30431207-BC59498D-B455-4FCE-B51F-D364E3573E2E

Q30431207-C485FCD8-B0DA-4296-80C6-D0DCD4F02B30

Q30431207-C9095221-D2E9-4475-BAAF-069A2FF9A8D2

P2860

Q30431207-14514E00-6F17-46FD-9B3F-955F411D4249

Q30431207-1994C2F3-B4FC-4AE1-82DA-939DB8860778

Q30431207-28B6771F-7698-4D8D-8524-3C29AFB4E610

Q30431207-2A1DA33C-065B-4395-B145-5B620619B33E

Q30431207-2CAE034C-642B-4DBF-9D40-E3FF69BDD2E8

Q30431207-2FF35F88-682F-4A34-A8D9-25A1536D35D2

Q30431207-37531407-7F98-4E7D-BB37-70AA0E54705E

Q30431207-37B48D4A-E9A1-4A31-9032-6F6FAAAE9549

Q30431207-3EE5184C-C618-484B-B1DD-9B7D39C2BF9C

Q30431207-4C24003C-3B9E-46CF-A186-B12D194BF9BB

P304

Q30431207-69EBB99B-C2A3-4B1C-BF0B-826781B613EB

P31

Q30431207-AE3084DF-7343-49B1-B2E4-A8C16CA90150

P356

Q30431207-25D28AFC-7D82-48F1-AD5E-0A1DE485C847

P407

Q30431207-42C4FD86-652B-4D97-88E0-4915AAAEF20F

P433

Q30431207-3C4ED6AD-C6C0-495D-B984-1FC9AE8DCE24

P478

Q30431207-A8EBCACB-3598-4D24-863F-D1893429DE6A

P50

Q30431207-3C34EBA5-DDDF-41D1-A95D-3DAF25EFFBC0

P577

Q30431207-32B660C0-438F-413F-8437-76406DBFC96F

P5875

Q30431207-B3853D81-925A-4524-B93E-703A291287A5

P698

Q30431207-6720B0F6-5815-4405-93ED-AAF76C71B518

P921

Q30431207-2FA5B6A6-3C0E-413C-A422-647F986B84E4

Q30431207-8D04E85A-2D0A-4644-9819-C04B1E5F223D

P932

Q30431207-FD1EB898-AB44-41B6-B013-761EEF6A9996

P356

J.1600-6143.2010.03046.X

P1433

American Journal of Transplantation

P1476

Impact of virologic breakthrou ...... ce after liver transplantation

@en

P2093

A S F Lok

http://www.w3.org/2001/XMLSchema#string

B Degertekin

http://www.w3.org/2001/XMLSchema#string

C Soldevila-Pico

http://www.w3.org/2001/XMLSchema#string

E B Keeffe

http://www.w3.org/2001/XMLSchema#string

E R Schiff

http://www.w3.org/2001/XMLSchema#string

M B Ishitani

http://www.w3.org/2001/XMLSchema#string

NIH HBV-OLT Study Group

http://www.w3.org/2001/XMLSchema#string

R S Brown

http://www.w3.org/2001/XMLSchema#string

S Emre

http://www.w3.org/2001/XMLSchema#string

Steven-Huy B Han

http://www.w3.org/2001/XMLSchema#string

P2860

Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir

Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.

Prevention of recurrent hepatitis B post-liver transplantation.

Management of hepatitis B in liver transplantation patients.

Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis.

P304

1823-1833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6143.2010.03046.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

K. Rajender Reddy

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42608796

http://www.w3.org/2001/XMLSchema#string

P698

20346062

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

P932

2910807

http://www.w3.org/2001/XMLSchema#string